GDTC CytoMed Therapeutics Ltd — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$0.99

Period return

+0.10 (+11.24%)

Volume

3.1M

2026-07-24O $0.9 H $1.02 L $0.9 C $0.99MA5 $0.96MA20 $0.99MA60 $1.04MA120 $1.03

6M · 125 barsYahoo Finance · USD2026-01-26 → 2026-07-24

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2024. 10. 10.LowBUY2 years ago
Benchmark: Speculative Buy
US analyst rating / recommendation change.
2024. 06. 11.LowBUY2 years ago
Benchmark: Speculative Buy
US analyst rating / recommendation change.
2023. 12. 04.LowBUY3 years ago
Benchmark: Speculative Buy
US analyst rating / recommendation change.
2023. 07. 21.MediumBUY3 years ago
Benchmark: Speculative Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Rating & price-target changes

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord-derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore; and Business and Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.

Sector: Healthcare
Industry: Biotechnology
HQ: Singapore, Singapore

CytoMed Therapeutics Ltd

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2024. 10. 10.	Benchmark	—	Maintain	Speculative Buy → Speculative Buy	—	Benchmark: Speculative Buy
2024. 06. 11.	Benchmark	—	Maintain	Speculative Buy → Speculative Buy	—	Benchmark: Speculative Buy
2023. 12. 04.	Benchmark	—	Maintain	Speculative Buy → Speculative Buy	—	Benchmark: Speculative Buy
2023. 07. 21.	Benchmark	—	Initiate coverage	— → Speculative Buy	—	Benchmark: Speculative Buy